/ /

  • linkedin
  • Increase Font
  • Sharebar

    European study with microstent demonstrates lowered IOP, use of fewer drugs

    Data focuses on patients with combined cataract surgery, device implantation

    Take-home message: Patients with cataract surgery and microstent implantation had a lowered IOP and a reduced number of medications used at 3 years postoperatively.

     

     

    Three-year results with the microinvasive glaucoma surgery (MIGS) device (CyPass Micro-Stent, Alcon Laboratories) combined with cataract surgery showed sustained IOP control and a lower need for glaucoma medications, said Steven R. Sarkisian Jr., MD.

    The device is placed in the supraciliary space and is implanted in an ab interno fashion via a clear cornea incision. This approach spares the conjunctiva, sclera, and trabecular meshwork.

    Two cohorts

    European data presented by Dr. Sarkisian from the multicenter prospective CyCLE study focused on two patient cohorts (245 eyes) that both had combined small-incision cataract surgery and device implantation. In one cohort (93 eyes), the patients had uncontrolled IOP (21 mm Hg or greater) at baseline.

    “The goal with this group was to lower the IOP,” said Dr. Sarkisian, clinical professor and Glaucoma Fellowship Director, Dean McGee Eye Institute, University of Oklahoma, Oklahoma City, OK.

    In a second cohort of 152 eyes, the IOP was controlled (21 mm Hg or lower), and the goal was to lower the number of medications used.

    The mean baseline IOP in cohort 1 was 25.3 mm Hg versus 16.4 mm Hg in cohort 2. At baseline, both groups used about 2.1 medications on average.

    Thirty-two patients in the study had previous glaucoma surgery, Dr. Sarkisian said

    After implantation of the device, the mean IOP in cohort 1 lowered from 25.3 mm Hg to 17.2 mm Hg at 3 years. At 12 and 24 months, the mean IOP in cohort 1 had lowered by 34% and 30%, respectively, he said.

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results